Cascade AI | $3,750,000 | (Oct 25, 2024)
Osigu | $25,000,000 | (Oct 25, 2024)
Outrider | $62,000,000 | (Oct 25, 2024)
Alpha-9 Oncology
United States
- Boston, Massachusetts
- 24/10/2024
- Series C
- $175,000,000
Alpha-9 Oncology is a clinical stage, radiopharmaceutical company developing differentiated and highly targeted radiopharmaceuticals with the potential to meaningfully improve the treatment of people living with cancer. Applying proprietary technologies and deep-foundational expertise, Alpha-9 is on the forefront of engineering bespoke radiopharmaceuticals that are optimized to selectively deliver radiation to tumor sites while minimizing off-target effects. Alpha-9 is advancing a robust pipeline of novel radiopharmaceuticals with a systematic approach to molecule design that offers broad potential for expansion into several validated oncology targets. Alpha-9 was founded by researchers from the University of British Columbia and BC Cancer, with the goal of improving the lives of patients affected by metastatic cancers.
- Industry Biotechnology Research
- Website https://www.a9oncology.com/
- LinkedIn https://www.linkedin.com/company/a9oncology/
OLOID | $6,000,000 | (Oct 25, 2024)
MoneyStack | $250,000 | (Oct 25, 2024)
Attention | $14,000,000 | (Oct 25, 2024)
BuildPass | $7,500,000 | (Oct 25, 2024)
Mave | $1,444,304 | (Oct 25, 2024)
Aether Energy (YC W24) | $2,500,000 | (Oct 25, 2024)
Pharos (YC S24) | $5,000,000 | (Oct 25, 2024)
Valon | $100,000,000 | (Oct 24, 2024)